NIS 793

Drug Profile

NIS 793

Alternative Names: NIS793

Latest Information Update: 09 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 25 Apr 2017 Phase-I clinical trials in Cancer (Late-stage disease, Monotherapy) in USA (Parenteral) (NCT02947165)
  • 25 Apr 2017 Phase-I clinical trials in Cancer (Combination therapy, Late-stage disease) in USA (Parenteral) (NCT02947165)
  • 08 Nov 2016 Novartis plans a phase I/Ib trial for Cancer (Monotherapy, Combination therapy, Late-stage disease) in USA, Canada, Europe and Asia (NCT02947165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top